Accueil / Communiqués / Myomo Makes NYSE American Section 610(b) Public Announcement

Myomo Makes NYSE American Section 610(b) Public Announcement

Friday, March 15th 2019 at 8:05pm UTC

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable
medical robotics company that offers increased functionality for those
suffering from neurological disorders and upper limb paralysis, today
announced that, as previously disclosed in its Annual Report on Form
10-K for the year ended December 31, 2018 filed on March 12, 2019 with
the Securities and Exchange Commission, the audited financial statements
for the year ended December 31, 2018 included in the 10-K contained an
audit opinion from its independent registered public accounting firm,
which included a going concern emphasis of matter paragraph.

This announcement is made pursuant to NYSE American Company Guide
Section 610(b), which requires separate public announcement of the
receipt of an audit opinion containing a going concern paragraph. This
announcement does not represent any change or amendment to the Company’s
consolidated financial statements or to its Annual Report on Form 10-K
for the year ended December 31, 2018.

About Myomo
Myomo, Inc. is a wearable medical robotics
company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb orthosis
designed to support the arm and restore function to the weakened or
paralyzed arms of patients suffering from CVA stroke, brachial plexus
injury, traumatic brain or spinal cord injury, ALS or other
neuromuscular disease or injury. It is currently the only marketed
device that, sensing a patient’s own EMG signals through non-invasive
sensors on the arm, can restore an individual’s ability to perform
activities of daily living, including feeding themselves, carrying
objects and doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered in
Cambridge, Massachusetts, with sales and clinical professionals across
the U.S. For more information, please visit www.myomo.com.

Forward Looking Statements
This press release contains
forward-looking statements regarding the Company’s future business
expectations, including the potential benefits of Myomo’s products for
their users, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are only predictions and may differ materially from actual
results due to a variety of factors.

These factors include, among other things:

  • our sales and commercialization efforts;
  • our ability to achieve reimbursement from third-party payers for our
    products;
  • our dependence upon external sources for the financing of our
    operations;
  • our ability to effectively execute our business plan; and
  • our expectations as to our clinical research program and clinical
    results.

More information about these and other factors that potentially could
affect our financial results is included in Myomo’s filings with the
Securities and Exchange Commission, including those contained in the
risk factors section of the Company’s annual report on Form 10-K,
subsequent quarterly reports on Form 10-Q and other filings with the
Commission. The Company cautions readers not to place undue reliance on
any such forward-looking statements, which speak only as of the date
made. Although the forward-looking statements in this release of
financial information are based on our beliefs, assumptions and
expectations, taking into account all information currently available to
us, we cannot guarantee future transactions, results, performance,
achievements or outcomes. No assurance can be made to any investor by
anyone that the expectations reflected in our forward-looking statements
will be attained, or that deviations from them will not be material and
adverse. The Company disclaims any obligation subsequently to revise any
forward-looking statements to reflect events or circumstances after the
date of such statements or to reflect the occurrence of anticipated or
unanticipated events.

Contacts

For Myomo:
ir@myomo.com

Investor
Relations:

Vivian Cervantes
PCG Advisory
646-863-6274
vivian@pcgadvisory.com

Public
Relations:

Matter Communications
Sarah Karr
978-518-4817
myomo@matternow.com

Source: Myomo, Inc.


Voir aussi

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Thursday, March 21st 2019 at 4:45pm UTC Executed strategic agreement for Imeglimin with Roivant Sciences; …